Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
INNOVAR is a fixed-dose combination injectable containing droperidol (a butyrophenone antipsychotic) and fentanyl citrate (a potent opioid agonist) indicated for anesthesia adjuncts and acute agitation management. The combination works synergistically: fentanyl provides analgesia and sedation via mu-opioid receptor agonism, while droperidol acts as a dopamine antagonist to enhance sedation and reduce nausea. This product is a legacy anesthetic agent repositioned for modern perioperative and acute care settings.
Pre-launch stage indicates early-stage commercialization planning; team size and hiring are likely ramping for market entry execution.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on INNOVAR in its pre-launch phase offers rare opportunity to build a brand from market entry, with heavy emphasis on launch execution, competitive positioning against entrenched anesthesia regimens, and managing legacy safety perception of droperidol. Career growth is tied to successful regulatory approval and commercial ramp, with roles spanning brand management, field engagement, and medical education.
Worked on INNOVAR at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.